**What is already known about the topic?**

-   Early palliative care has been shown to reduce acute care service use at the end of life, but findings are mostly limited to cancer patients receiving hospital-based palliative care interventions.

-   Recent studies show that both hospital- and community-based palliative care are associated with improved end-of-life outcomes, but never investigated the association between early versus late palliative care and end-of-life service utilization.

**What this paper adds?**

-   Includes palliative care services initiated in both hospital and community-based settings.

-   Early initiation of palliative care was associated with reduced acute-hospital use in the last 2 weeks of life.

-   Compared to cancer decedents, late palliative care had a notably greater association with increased acute care use in organ failure and frailty decedents.

**Implications for practice, theory or policy**

-   Clear disparities exist in palliative care timing for non-cancer decedents, suggesting that these populations may reap greater benefits if identified earlier. Addressing this gap would ultimately help reduce costly end-of-life acute-care service use.

-   Future research should examine effective interventions that would allow for earlier identification of patients (including cancer and non-cancer) who may benefit from timely palliative care. Differences in underlying characteristics of early and late palliative care recipients should also be further investigated.

Introduction {#section7-0269216318815794}
============

End-of-life discussions and interventions to control advanced symptoms often occur only during the last few weeks of life. This late initiation is often also associated with care that is primarily delivered in hospital settings---the default place of care when community-based care (i.e. in patient's homes) is not established early and adequately. Palliative care that is earlier on in the course of one's disease---and even concurrently with active treatments---can drastically improve symptom control, reduce distress experienced from standard therapies,^[@bibr1-0269216318815794][@bibr2-0269216318815794]--[@bibr3-0269216318815794]^ and can fulfill the wishes of many patients who prefer home-based care.^[@bibr4-0269216318815794][@bibr5-0269216318815794][@bibr6-0269216318815794]--[@bibr7-0269216318815794]^ Consequently, policymakers have made a push toward supporting more patients at home during end-of-life---a widely used administrative indicator of end-of-life quality that also strives to reduce acute-care service use.^[@bibr8-0269216318815794][@bibr9-0269216318815794][@bibr10-0269216318815794]--[@bibr11-0269216318815794]^

Past randomized controlled trials have illustrated that early palliative care is associated with better end-of-life outcomes.^[@bibr12-0269216318815794][@bibr13-0269216318815794]--[@bibr14-0269216318815794]^ For instance, a landmark study by Temel et al.^[@bibr13-0269216318815794]^ demonstrated that early palliative care delivered concurrently with standard oncologic care was associated with improved quality of life, reduced depressive symptoms, longer survival rates, and less aggressive care at the end of life. Although informative, results from these trials were limited to cancer patients who received hospital-based palliative care interventions. Recent research shows that community-based palliative care may also lead to improvements---such as reduced acute-hospital use and hospital deaths---but never investigated the impact of early versus late palliative care on end-of-life service use and mainly focused on small populations (mostly cancer) receiving care from a particular setting.^[@bibr15-0269216318815794][@bibr16-0269216318815794][@bibr17-0269216318815794][@bibr18-0269216318815794][@bibr19-0269216318815794][@bibr20-0269216318815794][@bibr21-0269216318815794][@bibr22-0269216318815794][@bibr23-0269216318815794]--[@bibr24-0269216318815794]^ Furthermore, a large abundance of existing palliative care research uses late-life acute hospitalizations as an outcome to indicate poor quality care. However, not all hospitalizations are considered inappropriate as some involve a palliative care approach; despite this, most research does not differentiate between those who did and did not receive palliative care in acute settings.

To address these knowledge gaps, we conducted a population-based retrospective cohort study of cancer and non-cancer Ontario decedents to investigate the association between early versus late palliative care and acute-hospital use in the last 2 weeks of life. Our study specifically provides information on acute-hospital use with and without palliative care involvement during the hospitalization. We also report on all other end-of-life services used in a publicly funded healthcare system and assess disease-specific trends (frailty, organ failure, cancer). Our study advances prior work by investigating the association between palliative care (both hospital- and community-based) timing and end-of-life service use, which can inform other countries with similar or different healthcare systems.

Methods {#section8-0269216318815794}
=======

Study design and data sources {#section9-0269216318815794}
-----------------------------

We conducted a retrospective cohort study of Ontario decedents aged 18 years or older, capturing all deaths from 1 April 2010 to 31 December 2012. To identify all services used across several health sectors in the last 2 weeks of life (defined as: 1--14 days before death + date of death (day 0)), patient data were linked using multiple administrative databases held at ICES^[@bibr25-0269216318815794]^, including the Vital Statistics Database (Office of the Registrar General---Deaths), which captured place, cause, and date of death; Registered Persons Database, which captured all demographic information including sex, age, and postal code; Ontario Health Insurance Plan Claims Database, which captured all claims data for physician services in both inpatient and outpatient settings; Home Care Database, capturing publicly funded home care services; Discharge Abstract Database, capturing all acute-care use, including acute care with and without palliative care (identified using a previously derived comprehensive list of palliative care billing codes);^[@bibr26-0269216318815794],[@bibr27-0269216318815794]^ National Ambulatory Care Reporting System, which captured all emergency department visits; Continuing Care Reporting System, capturing care provided in long-term care and complex continuing care (i.e. equivalent to subacute care settings); and Statistics Canada Census data, which captured income quintile and rurality via postal codes.^[@bibr28-0269216318815794]^

Five distinct categories exist for causes of death: terminal illness (e.g. cancer), organ failure (e.g. chronic heart failure), frailty (e.g. Alzheimer's disease), sudden death (e.g. accident), and other;^[@bibr28-0269216318815794][@bibr28-0269216318815794]--[@bibr30-0269216318815794]^ these cohorts have been previously used in Canada.^[@bibr31-0269216318815794],[@bibr32-0269216318815794]^ In this study, we refer to these categories as 'disease cohorts'. Decedents were assigned to a disease cohort based on the underlying cause of death code (10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10)-CA diagnosis code) found in the vital statistics records, as defined previously.^[@bibr31-0269216318815794]^ For clarity, we replaced the label 'terminal illness' with 'cancer' since the majority of individuals in this disease cohort had a cancer-related death. Decedents in the 'sudden death' and 'other' cohorts were excluded in our analyses due to their small numbers and because of the diminished potential role of palliative care in many cases.

Exposure {#section10-0269216318815794}
--------

The main exposure was time from first palliative care initiation to death from hospital or community, defined as the first instance of any palliative care service captured in the last year of life. We used a previously derived comprehensive list of palliative care billing codes to identify each individual's date of palliative care initiation prior to death.^[@bibr27-0269216318815794]^ The timing of the exposure was calculated by finding the difference (in days) between an individual's date of death and date of palliative care initiation. We categorized decedents into the following recipient groups, according to initiation time before death: *early* (⩾60 days), *late* (⩾15 to \<60 days), *very late* (⩾0 to ⩽14 days), and *never* (no initiation). Cut-offs for these categories were chosen based on expert opinion consensus and previous literature proposing similar timeframes for defining palliative care receipt.^[@bibr33-0269216318815794],[@bibr34-0269216318815794]^ Note that we mainly focus on comparing early versus late recipients and exclude 'very late' recipients from much of our analyses; this was done to avoid confounding issues due to overlap with the outcome period (i.e. it would be unclear if palliative care was initiated prior to or after use of acute care within the last 2 weeks of life).

Outcomes {#section11-0269216318815794}
--------

The primary outcome was use of acute-care and community services during the last 2 weeks of life. We classified these services by care settings. Acute-care settings were composed of (1) 'palliative-acute care', defined as an acute-hospital admission that had palliative involvement, and (2) 'non-palliative-acute care', defined as an acute-hospital admission without any palliative involvement.^[@bibr27-0269216318815794]^ Other outcomes we examined include subacute care, emergency department, and community-based care (home care, home-based physician visits, and outpatient physician encounters). Within acute-care admissions, all days prior to discharge were counted as a palliative care day (i.e. deemed palliative-acute care) for the entire duration of stay when a decedent had a pre-admitting condition listed as palliative care or the most responsible diagnosis for the hospital stay was also palliative, the main service provider was palliative, or palliative care was consulted for the largest portion of their hospital stay. For all remaining palliative-acute-care encounters, only a single day of the hospitalization was counted as a palliative care day (e.g. individuals initially admitted as acute-care patients but later received a palliative diagnosis at some point during their hospital stay). This approach indirectly captures designated palliative care unit beds in acute hospitals and also palliative care services provided when another admitting service was the main provider service.

Statistical analysis {#section12-0269216318815794}
--------------------

Descriptive statistics were used to compare cohort characteristics between early versus late palliative care recipients. Characteristics include sex, age, income quintile, rurality, chronic diseases, number of comorbidities, place of death, mean and median time to first palliative care initiation before death, and palliative care initiation sector. Multivariable logistic regression analyses were used to predict in the 2 weeks before death: the likelihood of using an acute-care setting and the likelihood of spending \>1 week in acute-care settings. We adjusted for the following covariates in the models: sex, age, income quintile, rurality, and number of comorbidities. Ethics approval for this study was received from the Ottawa Hospital Research Institute Ethics Board in Ottawa, Canada. All analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA).

Results {#section13-0269216318815794}
=======

We identified 230,921 decedents during the study period, who spent an average of 5.1 days in acute-care settings (of whom 60% had at least one service day in the last 2 weeks of life). Overall, 33% of decedents died from cancer, 31% from organ failure, 29% from frailty, 3% had a sudden death, and 5% from other causes. Almost half (46%) of decedents never received palliative care, and the remaining decedents were split by early palliative care (27%) and late or very late recipients (27%; [Table 1](#table1-0269216318815794){ref-type="table"}). The majority of early and late recipients died from cancer (67% and 53%, respectively), while a large portion of very late recipients died from organ failure (40%). Notably, more than half of cancer decedents were early recipients (56%). Overall, 61% of the study population experienced a hospital-based death, and more late recipients (73%) died in hospital compared to early recipients (60%) ([Table 2](#table2-0269216318815794){ref-type="table"}).

###### 

Cohort characteristics.

![](10.1177_0269216318815794-table1)

  Characteristic                                                     Early    Late   Very Late   Never   Overall                                 
  ------------------------------------------------------------------ -------- ------ ----------- ------- --------- ---- --------- ---- --------- -----
  *Overall*                                                          62,728   27     29,710      13      31,549    14   106,934   46   230,921   100
  *Disease cohort*                                                                                                                               
   Frailty                                                           7893     12     5231        8       8202      12   45,467    68   66,793    29
   Organ failure                                                     11,103   16     7480        11      12,511    18   39,596    56   70,690    31
   Cancer                                                            42,255   56     15,672      21      8422      11   8841      12   75,190    33
   Sudden death                                                      166      2      162         2       344       5    6781      91   7453      3
   Other                                                             1311     12     1165        11      2070      19   6249      58   10,795    5
  *Sex*                                                                                                                                          
   Female                                                            32,081   27     14,940      13      16,752    14   54,850    46   118,623   51
   Male                                                              30,647   27     14,770      13      14,797    13   52,084    46   112,298   49
  *Age* (years)                                                                                                                                  
   18--44                                                            1493     21     391         6       347       5    4788      68   7019      3
   45--64                                                            13,057   35     4409        12      3455      9    16,234    44   37,155    16
   65--84                                                            32,041   31     14,692      14      14,302    14   43,276    41   104,311   45
   85 +                                                              16,137   20     10,218      12      13,445    16   42,636    52   82,436    36
  *Income* ^[a](#table-fn1-0269216318815794){ref-type="table-fn"}^                                                                               
   Lowest                                                            13,362   25     6513        12      7347      14   25,540    48   52,762    23
   Low                                                               13,116   27     6311        13      6669      14   22,099    46   48,195    21
   Middle                                                            11,983   27     5818        13      5962      13   20,720    47   44,483    19
   High                                                              12,141   28     5663        13      5919      14   19,689    45   43,412    19
   Highest                                                           11,858   29     5267        13      5465      13   18,081    44   40,671    18
  *Ruralitya*                                                                                                                                    
   Urban                                                             53,978   27     25,780      13      27,221    14   89,977    46   196,956   85
   Rural                                                             8689     26     3897        12      4288      13   16,745    50   33,619    15
  *Chronic diseases*                                                                                                                             
   Hypertension                                                      45,150   26     22,538      13      25,051    14   80,611    47   173,350   75
   Osteoarthritis                                                    31,523   28     14,658      13      15,872    14   52,080    46   114,133   49
   Cancer                                                            47,786   47     18,516      18      12,441    12   23,296    23   102,039   44
   Diabetes                                                          21,735   26     10,398      13      11,380    14   38,871    47   82,384    36
   Congestive heart failure                                          18,305   23     9415        12      12,273    16   38,882    49   78,875    34
   Coronary heart disease                                            18,422   24     9088        12      11,127    15   37,309    49   75,946    33
   Dementia                                                          12,132   18     7159        11      10,099    15   36,970    56   66,360    29
   COPD                                                              15,866   27     7373        13      9005      15   26,393    45   58,637    25
   Renal disease                                                     14,703   27     7399        13      9245      17   23,986    43   55,333    24
  No. of comorbidities                                                                                                                           
   0                                                                 131      2      163         3       298       5    4855      89   5447      2
   1--2                                                              12,297   29     5346        12      4722      11   20,777    48   43,142    19
   3--5                                                              31,082   28     15,284      14      15,579    14   48,664    44   110,609   48
   6+                                                                19,218   27     8917        12      10,950    15   32,638    46   71,723    31

Does not equal 100%: a very small number of records are missing this information.

###### 

Palliative care delivery and place of death.

![](10.1177_0269216318815794-table2)

  Characteristic                            Early                 Late              Very late     Never   Overall
  ----------------------------------------- --------------------- ----------------- ------------- ------- -------------------
  Place of palliative care initiation (%)                                                                 
   Hospital                                 54                    74                83            N/A     35
   Long-term care                           0.2                   0.3               0.8           N/A     0.2
   Community                                45                    26                16            N/A     18
  Initiation time before death (days)                                                                     
   Mean, median (IQR)                       210, 201 (116, 307)   32, 30 (21, 42)   6, 6 (3, 9)   N/A     114, 59 (13, 200)
  Place of death (%)                                                                                      
   Hospital                                 60                    73                83            52      61
   Long-term care                           11                    10                11            28      19
   Community                                29                    17                6             21      20

Palliative care initiations {#section14-0269216318815794}
---------------------------

Early recipients initiated palliative care at a mean time of 210 days prior to death, compared with a mean of 32 days for late recipients ([Table 2](#table2-0269216318815794){ref-type="table"}). Overall, 45% of early recipients initiated in a community-based setting, which was almost two times greater than the proportion of late recipients (26%). Late recipients had considerably more hospital-based initiations (74%) when compared to early recipients (54%). Disease-specific differences show that organ failure and frailty decedents had the most hospital-based initiations (82% and 73%, respectively), while cancer decedents had the most community-based initiations (44%).

Place of care utilization trends (among service users) {#section15-0269216318815794}
------------------------------------------------------

About 63% of early recipients used an acute-care setting at least once in the last 2 weeks of life (spent 9.2 mean days), compared to 80% of late recipients (spent 11.7 mean days; [Table 3](#table3-0269216318815794){ref-type="table"}). Early and late recipients had a similar proportion of non-palliative-acute-care users (26% and 23%, respectively), with similar days of service use (6.4 and 6.8 mean days, respectively). Compared to late recipients, fewer early recipients used palliative-acute care (65% vs 42%) and spent less service days (9.6 vs 12 mean days) in the last 2 weeks of life. In addition, early recipients made more use of community-based care, having almost double the percentage of individuals receiving home-based physician visits compared to late recipients (28% vs 17%).

###### 

Place of care utilization by palliative care initiation time before death (among users).

![](10.1177_0269216318815794-table3)

  Place of care                                          Palliative care initiation time                 
  ------------------------------------------------------ --------------------------------- ------------- ------------
  *Care in hospitals/institutions*                                                                       
   Acute-care settings: mean days (% users)              9.2 (62.5)                        11.7 (79.8)   7.3 (44.6)
   Non-palliative-acute care: mean days (% users)        6.4 (26.4)                        6.8 (22.8)    7.3 (44.6)
   Palliative-acute care: mean days (% users)            9.6 (42.3)                        12 (65.2)     0 (0)
   Emergency department: mean days (% users)             1.8 (32.5)                        1.6 (25.3)    1.6 (44.6)
   Subacute care: mean days (% users)                    11.3 (16.9)                       9.6 (13.6)    12.2 (3.6)
   Long-term care: mean days (% users)                   13.3 (11.6)                       12.8 (9.9)    14.1 (32)
  *Care in the community*                                                                                
   Home care: mean days (% users)                        7.4 (55.4)                        5.9 (42.5)    4.9 (19.2)
   Home-based physician visit: mean days (% users)       2.4 (28)                          2.1 (16.6)    1.1 (7.5)
   Outpatient physician encounter: mean days (% users)   2.9 (69.9)                        2.8 (69.5)    1.6 (43.5)

Multivariable analyses {#section16-0269216318815794}
----------------------

When examining the odds of using acute-care settings, late recipients from each disease cohort have a higher odds ratio (OR; cancer: OR = 2.31, 95% confidence interval (CI): 2.30--2.32, frailty: OR = 3.05, 95% CI: 3.03--3.07, organ failure: OR = 3.25, 95% CI: 3.23--3.27) compared to early recipients, controlling for covariates ([Table 4](#table4-0269216318815794){ref-type="table"}). Similarly, when examining the odds of spending \>1 week in acute-care settings during the last 2 weeks of life, late recipients have a higher OR (cancer: OR = 1.84, 95% CI: 1.83--1.85, frailty: OR = 3.04, 95% CI: 3.01--3.07, and organ failure: OR = 4.04, 95% CI: 4.02--4.06) compared to early recipients. An increasing number of comorbidities was also associated with increased odds of using acute-care settings and increased odds of spending \>1 week in acute-care settings---especially for those with frailty.

###### 

Multivariate logistic regression: (1) odds of ever using acute-care settings in the last 2 weeks of life, and (2) odds of spending \>1 week in acute-care settings in the last 2 weeks of life.

![](10.1177_0269216318815794-table4)

  Exposure               Odds of ever using acute-care settings in the last 2 weeks of life   Odds of spending \>1 week in acute-care settings in the last 2 weeks of life                                                               
  ---------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------- ------------------- ------------------- -------------------
   Early                 Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   Late                  2.31 (2.3, 2.32)                                                     3.05 (3.03, 3.07)                                                              3.25 (3.23, 3.27)   1.84 (1.83, 1.85)   3.04 (3.01, 3.07)   4.04 (4.02, 4.06)
   Never                 0.96 (0.95, 0.97)                                                    0.52 (0.51, 0.53)                                                              0.61 (0.6, 0.62)    0.77 (0.75, 0.79)   0.41 (0.39, 0.43)   0.48 (0.47, 0.49)
  Sex                                                                                                                                                                                                                                    
   Male                  Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   Female                0.8 (0.79, 0.81)                                                     0.66 (0.65, 0.67)                                                              0.76 (0.75, 0.77)   1.06 (1.05, 1.07)   0.87 (0.86, 0.88)   0.87 (0.86, 0.88)
  Age (years)                                                                                                                                                                                                                            
   18--44                1.88 (1.85, 1.91)                                                    1.57 (1.51, 1.63)                                                              1.41 (1.38, 1.44)   1.29 (1.26, 1.32)   1.52 (1.43, 1.61)   1.06 (1.02, 1.1)
   45--64                1.4 (1.39, 1.41)                                                     1.06 (1.04, 1.08)                                                              1.16 (1.15, 1.17)   1 (0.99, 1.01)      0.88 (0.85, 0.91)   1.09 (1.07, 1.11)
   65--84                Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   85+                   0.6 (0.59, 0.61)                                                     0.61 (0.6, 0.62)                                                               0.52 (0.51, 0.53)   0.95 (0.94, 0.96)   0.84 (0.82, 0.86)   0.82 (0.81, 0.83)
  Income                                                                                                                                                                                                                                 
   Lowest                Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   Low                   0.96 (0.95, 0.97)                                                    1.04 (1.03, 1.05)                                                              1.07 (1.06, 1.08)   1 (0.98, 1.02)      0.97 (0.95, 0.99)   0.95 (0.93, 0.97)
   Middle                0.9 (0.89, 0.91)                                                     0.97 (0.96, 0.98)                                                              1 (0.99, 1.01)      0.98 (0.96, 1)      0.95 (0.93, 0.97)   0.93 (0.91, 0.95)
   High                  0.9 (0.89, 0.91)                                                     0.95 (0.94, 0.96)                                                              1.05 (1.04, 1.06)   0.94 (0.92, 0.96)   0.99 (0.97, 1.01)   0.96 (0.94, 0.98)
   Highest               0.82 (0.81, 0.83)                                                    0.94 (0.93, 0.95)                                                              1.02 (1.01, 1.03)   0.95 (0.93, 0.97)   0.92 (0.9, 0.94)    0.88 (0.86, 0.9)
  Rurality                                                                                                                                                                                                                               
   Urban                 Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   Rural                 1.11 (1.1, 1.12)                                                     0.99 (0.98, 1)                                                                 0.95 (0.94, 0.96)   1 (0.99, 1.01)      0.92 (0.9, 0.94)    0.91 (0.89, 0.93)
  No. of comorbidities                                                                                                                                                                                                                   
   0                     Ref.                                                                 Ref.                                                                           Ref.                Ref.                Ref.                Ref.
   1                     3.45 (3.38, 3.52)                                                    2.23 (2.18, 2.28)                                                              1.76 (1.72, 1.8)    1.18 (1.06, 1.3)    1.54 (1.44, 1.64)   1.13 (1.07, 1.19)
   2                     4.14 (4.07, 4.21)                                                    3.07 (3.02, 3.12)                                                              2.44 (2.41, 2.47)   1.37 (1.25, 1.49)   1.58 (1.49, 1.67)   1.18 (1.13, 1.23)
   3                     4.77 (4.7, 4.84)                                                     4.48 (4.44, 4.52)                                                              2.97 (2.94, 3)      1.45 (1.33, 1.57)   1.85 (1.76, 1.94)   1.39 (1.34, 1.44)
   4                     5.01 (4.94, 5.08)                                                    5.86 (5.82, 5.9)                                                               3.51 (3.48, 3.54)   1.66 (1.54, 1.78)   1.99 (1.9, 2.08)    1.58 (1.53, 1.63)
   5                     5.52 (5.45, 5.59)                                                    7.76 (7.72, 7.8)                                                               4.36 (4.33, 4.39)   1.57 (1.45, 1.69)   2.23 (2.14, 2.32)   1.67 (1.62, 1.72)
   6                     6.38 (6.31, 6.45)                                                    12.03 (11.99, 12.07)                                                           5.51 (5.48, 5.54)   1.74 (1.62, 1.86)   2.53 (2.44, 2.62)   1.9 (1.85, 1.95)
                         *Ref: Never Used Acute-Care Settings*                                *Ref: Spent \<1 Week in Acute-Care Settings*                                                                                               

Place of care utilization trajectories {#section17-0269216318815794}
--------------------------------------

We examined the percentage of patients using hospital-based care on each day within the last 2 weeks of life by disease cohort and by early versus late initiation times ([Figure 1](#fig1-0269216318815794){ref-type="fig"}). Late palliative care recipients used a consistently high proportion of acute-care services (palliative + nonpalliative) across the entire duration of the last 2 weeks of life (consistently over 50%). Although early recipients experienced notable increases in acute-care service use as death got closer, the proportion was always well below that of late recipients. These differing trends of acute-care service utilization in early versus late recipients were consistent across all three disease cohorts. Palliative-acute-care accounted for most of the acute-care service use for both early and late recipients.

![Disease-specific utilization trends of hospital-based care by palliative care initiation time.](10.1177_0269216318815794-fig1){#fig1-0269216318815794}

Discussion {#section18-0269216318815794}
==========

To our knowledge, this is the first study of its kind that uses population-based data from a universal healthcare system to study the association between early versus late palliative care and a rich set of services used at the end-of-life by both cancer and non-cancer patients. Our study findings show that early palliative care (as opposed to late palliative care) was associated with improved outcomes near the end of life. In the 2 weeks before death, early recipients had lower odds of using acute care and lower odds of spending \>1 week in acute care compared to late recipients. Moreover, we found that early recipients made greater use of community-based services. Many early initiations occurred in a community-based setting, while late initiations occurred mainly in hospital. Early recipients had twice as many community-based deaths and 13% less hospital-based deaths; early recipients were largely receiving out-of-hospital care, such as within the home, while most late recipients remained hospitalized throughout the last 2 weeks of life.

Reducing end-of-life acute-care service use is an indicator of higher quality of care^[@bibr35-0269216318815794]^ while lowering healthcare costs.^[@bibr36-0269216318815794]^ Past research has also shown that early palliative care (defined variably, ranging from 1 to 6 months before death) is associated with reduced end-of-life acute-care service use. Seow and colleagues previously conducted a population-based analysis of Ontario decedents, showing that early home-based palliative care reduced the risk of needing acute care in the last 2 weeks of life.^[@bibr19-0269216318815794]^ Several US cancer studies also highlight the benefits of early palliative care which include less aggressiveness at the end of life,^[@bibr13-0269216318815794]^ fewer hospital admissions, and reduced hospital-based deaths.^[@bibr37-0269216318815794],[@bibr38-0269216318815794]^ Similarly in Western Australia, earlier community-based palliative care was found to reduce acute-hospital stays,^[@bibr22-0269216318815794]^ emergency department use,^[@bibr18-0269216318815794]^ and unplanned hospitalizations.^[@bibr23-0269216318815794]^ Moreover, a Singapore study found that earlier referrals to hospital-based palliative care was associated with a higher likelihood of dying out of hospital.^[@bibr39-0269216318815794]^ Several European studies also reach similar conclusions.^[@bibr15-0269216318815794],[@bibr40-0269216318815794]^

Frailty and organ failure decedents received a late initiation of palliative care more often than cancer decedents, which was also associated with poorer outcomes in the last 2 weeks of life. We found that frailty and organ failure decedents were three times and four times more likely, respectively, to spend a greater duration of time in acute-care hospitals (compared to their early counterparts). A late initiation similarly influenced cancer decedents, but the association was not as pronounced. Several factors may explain these findings. First, non-cancer patients tend to receive lower quality end-of-life care than cancer patients.^[@bibr41-0269216318815794]^ Also, the setting of end-of-life care---which is known to be a key driver of disease-specific disparities^[@bibr41-0269216318815794]^---may play a role; our data show that late palliative care provided to organ failure and frailty decedents was initiated mostly in hospital, which may not necessarily be the most appropriate care setting. Non-cancer populations also experience greater incongruence between their care preferences and what happens in reality. Differences in trajectory of functional decline and its predictability may also explain our findings; for instance, patients with organ failure experience an end-of-life trajectory marked by acute exacerbations, warranting a greater need for acute-care services.^[@bibr28-0269216318815794],[@bibr42-0269216318815794]^ Therefore, earlier identification and increased understanding of patient needs may help improve palliative care provision; accomplishing this requires extensive knowledge of the trajectories of functional decline, existing comorbidities, and the social and environmental circumstances under which care is provided.

Strengths and limitations {#section19-0269216318815794}
-------------------------

Past studies examine recipients of hospital-based palliative care or community-based services, but not both together. A major strength of this study is the inclusion of a population-based sample from Ontario, Canada, where patients rely on a universal health system in which they are provided with concurrent access to hospital and community palliative care services without needing to forego curative treatment. Unlike the United States, where patients are required to forego curative care to be eligible for the Medicare Hospice Benefit at the end of life, we are able to observe palliative care provision in the entire population. Thus, our data are largely generalizable to other high-income countries with similar publicly funded healthcare (i.e. United Kingdom and Australia). Another strength of our study is that we include cancer and non-cancer decedents and a large set of health sectors to observe various services used at the end of life. We also capture officially and unofficially designated palliative beds in acute-care hospitals, allowing us to distinguish palliative- from non-palliative-acute-care use; this information lets us gauge which end-of-life hospitalizations were appropriate or inappropriate and serves as a useful comparator for other countries whose systems may or may not allow for such distinctions to be made.

Our study has several limitations. First, our study does not address the quality of care being delivered, nor do we describe the intensity of palliative care services provided in acute hospitals. Second, residential (i.e. free-standing) hospice facilities were not included as a place of care setting due to the lack of a central hospice database. About 1%--3% of individuals die in hospice annually, though most who do so use services such as home care or palliative-acute care---which is included in our study---before being admitted to a hospice. Moreover, our study only includes home care services that are publicly funded. In addition, relying mainly on physician billing codes might undercount palliative care provision in long-term care (where a large portion of frailty patients reside) as many individuals receive palliative care services from nurses or personal support workers in this setting, which are not billed under publicly funded home care---the latter of which we did capture. Our findings may also be susceptible to indication bias; patients initiating late palliative care are often close to death with more unstable conditions and thus more likely to receive care in acute settings at the end of life. Early palliative care recipients may also have distinct underlying characteristics than late recipients, such as differences in care preferences and disease symptoms (which we could not measure). Moreover, several important factors may play a role in explaining our finding of more aggressive end-of-life care among organ failure and frailty patients. These factors include lack of access to early palliative care^[@bibr43-0269216318815794]^ and challenges in early identification for a palliative care approach among non-cancer patients.^[@bibr44-0269216318815794],[@bibr45-0269216318815794]^ Healthcare providers also seem to experience difficulty in determining the end-of-life stage for non-cancer patients^[@bibr46-0269216318815794]^ and feel ill-prepared in making end-of-life prognostications due to perceived unpredictability of the disease course.^[@bibr47-0269216318815794],[@bibr48-0269216318815794]^ For example, it may be challenging to know when to initiate palliative care for patients with heart failure, who get hospitalized for exacerbations, but later discharged having regained some of their prior physical function.

Conclusion {#section20-0269216318815794}
==========

In conclusion, this study demonstrates that early palliative care is associated with reduced acute-hospital use (with or without palliative involvement) in the last 2 weeks of life. Clear disparities exist in palliative care timing, with organ failure and frailty decedents receiving late palliative care more often than early. These findings suggest that non-cancer populations might reap greater benefits if identified earlier for palliative care, which may also help reduce costly end-of-life acute-care service use. Future research should examine effective interventions that would allow for earlier identification of patients (including cancer and non-cancer) who may benefit from timely palliative care. Differences in the underlying characteristics of early and late palliative care recipients should also be further investigated.
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